top of page

The powerhouse of the cell

Driving a new means of fighting disease

Overview of our Patent-Pending MOT™ Technology

While conducting cancer research in the U.S., the benefits of mitochondria transplantation were discovered and exclusively licensed to MitoSense, under the name Mitochondria Organelle Transplantation (MOT™).  During the past two years, MOT™ has shown tremendous promise in early research and testing. This early evidence indicates MOT™ may alleviate some symptoms associated with neurodegenerative disorders such as ALS, Alzheimer’s, Parkinson’s, and others. Further research and testing are under way.

There is currently no other therapy available like MOT™ and the early indications point to much broader applications, that could benefit millions of Americans suffering from various neurodegenerative issues and diseases. 

Watch the promise of Mitochondria Organelle Transplantation (MOT™) to fight neurodegenerative diseases.

Validating Science

  • NASA research has identified mitochondrial health as a crucial component to the future of space travel 

  • Mayo Clinic research in 2012 discovered that mitochondrial dysfunction is present early in Alzheimer's disease before memory loss. 

  • Additional Alzheimer's research has shown that boosting mitochondrial health in mice reduced the number of amyloid plaques, thus resulting in improved cognitive function.

  • A study by the Buck Institute makes the case for boosting mitochondrial health as a means of slowing down or even reversing the effects of Alzheimer's and other neurodegenerative diseases.

Path Forward

We are actively forming partnerships with various public and private institutions  to expand our research and reach, so we can help improve as many lives as possible.

bottom of page